Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Biib save search
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
leqembi fda disease license treatment alzheimer's application submission
Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BAX | $41.02 1.54% 0.0% 2.6M
|
Health Technology
|
| O: 0.02%
H: 1.03%
C: 0.96%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.11%
H: 0.59%
C: 0.1%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.48%
H: 0.31%
C: 0.13%
reach cancer treatment global market
Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million, 42% of market growth is expected in North America, Technavio
Published: 2024-03-12 (Crawled : 04:00) - prnewswire.com
ELDN | $2.15 6.44% 6.05% 190K
|
Manufacturing
|
| O: 1.73%
H: 1.7%
C: -7.39%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
DNLI | $16.11 0.75% 0.74% 1.1M
|
Health Technology
|
| O: -0.6%
H: 0.74%
C: -3.66%
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: -2.43%
H: 2.8%
C: -4.02%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.86%
expected sclerosis treatment growth market
Listeria Monocytogenes Infections Treatment Global Market Report 2024: Global Expansion in Listeria Monocytogenes Treatment Sector Predicted Amid Rising Foodborne Disease Incidence
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: -0.63%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 0.87%
H: 0.21%
C: -2.23%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.89%
H: 0.41%
C: 0.1%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: 0.56%
H: 0.49%
C: -0.12%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.75%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
disease report treatment expansion global infections market
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
SAGE | $12.94 0.39% 0.39% 810K
|
Health Technology
|
| O: 3.04%
H: 0.0%
C: -3.59%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.56%
H: 1.74%
C: -0.18%
depression treatment women
Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million from 2023 to 2028, North America to account for 42% of market growth - Technavio
Published: 2023-12-07 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.06%
H: 0.82%
C: 0.82%
ELDN | $2.15 6.44% 6.05% 190K
|
Manufacturing
|
| O: -1.59%
H: 7.26%
C: 2.42%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
DNLI | $16.11 0.75% 0.74% 1.1M
|
Health Technology
|
| O: -0.21%
H: 0.08%
C: -1.76%
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: 0.0%
H: 3.56%
C: -9.77%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.61%
H: 1.33%
C: 0.69%
america sclerosis treatment growth market
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
Published: 2023-10-25 (Crawled : 15:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.88%
H: 0.34%
C: -1.27%
disease alzheimer’s tau promise potential
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
Published: 2023-09-25 (Crawled : 05:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -0.81%
leqembi disease japan approved alzheimer’s treatment
Myasthenia Gravis Treatment Market to Grow Exponentially by 2029 | Brandessence Market Research
Published: 2023-09-18 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 2.7%
H: 0.0%
C: -5.11%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.72%
H: 0.13%
C: -0.93%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.02%
H: 0.18%
C: -0.78%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.06%
H: 0.44%
C: -0.64%
treatment research market
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Published: 2023-08-05 (Crawled : 04:20) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
| Email alert
Add to watchlist
SAGE | $12.94 0.39% 0.39% 810K
|
Health Technology
| Email alert
Add to watchlist
fda approved treatment women response
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-07-07 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.21%
H: 0.34%
C: -3.68%
leqembi fda disease approval treatment alzheimer's grants
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Published: 2023-06-09 (Crawled : 23:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
| Email alert
Add to watchlist
leqembi fda disease alzheimer’s treatment
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
Published: 2023-05-15 (Crawled : 23:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.41%
H: 0.01%
C: -0.96%
drug disease health alzheimer’s treatment lecanemab canada submission
Global Rare Neurological Disease Treatment Market Report 2023: Promising Pipeline Drugs for Treatment of Rare Neurological Diseases Drives Growth
Published: 2023-04-28 (Crawled : 01:00) - prnewswire.com
CSLLY | $89.17 3.3% 54K
|
n/a
|
| O: -1.61%
H: 0.55%
C: 0.52%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.79%
H: 0.89%
C: 0.72%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.06%
H: 3.94%
C: 3.51%
rare disease report pipeline treatment global neurological growth market
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
Published: 2023-04-25 (Crawled : 21:00) - biospace.com/
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.68%
H: 1.01%
C: -2.97%
fda association approval treatment
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Published: 2023-04-25 (Crawled : 20:00) - globenewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.03%
H: 0.77%
C: -0.39%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -1.35%
H: 3.82%
C: 3.39%
fda genetic als approval treatment grants
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Published: 2023-03-05 (Crawled : 00:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.09%
H: 0.79%
C: -0.09%
treatment fda disease application grants license approval alzheimer’s review
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:20) - biospace.com/
SAGE | $12.94 0.39% 0.39% 810K
|
Health Technology
|
| O: 0.27%
H: 6.75%
C: 3.25%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.51%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression major depressive disorder
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:00) - globenewswire.com
SAGE | $12.94 0.39% 0.39% 810K
|
Health Technology
|
| O: 0.27%
H: 6.75%
C: 3.25%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.51%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression major depressive disorder
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Published: 2023-01-26 (Crawled : 00:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.15%
H: 1.21%
C: -0.78%
treatment lecanemab disease application alzheimer’s authorization
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.